Dexmedetomidine reduces in-hospital mortality in aneurysmal subarachnoid hemorrhage patients by modulating three key genes and inflammatory pathways: insights from clinical and bioinformatics analyses
BackgroundAneurysmal subarachnoid hemorrhage (aSAH) is a cerebrovascular disease with high mortality. Dexmedetomidine has a neuroprotective effect. This study aimed to explore the clinical and molecular association between dexmedetomidine and in-hospital mortality of aSAH.MethodsPatients with aSAH i...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1554809/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849387564427902976 |
|---|---|
| author | Zhi-ang Li Hong-cai Wang Xue-wei Zhang Li-hong Hu |
| author_facet | Zhi-ang Li Hong-cai Wang Xue-wei Zhang Li-hong Hu |
| author_sort | Zhi-ang Li |
| collection | DOAJ |
| description | BackgroundAneurysmal subarachnoid hemorrhage (aSAH) is a cerebrovascular disease with high mortality. Dexmedetomidine has a neuroprotective effect. This study aimed to explore the clinical and molecular association between dexmedetomidine and in-hospital mortality of aSAH.MethodsPatients with aSAH in the MIMIC-IV database were included and divided into non-in-hospital mortality and in-hospital mortality groups. Two machine learning algorithms random forest (RF) and XGBoost ranked treatment variables, and overlapping variables between these two algorithms were selected to evaluate their prognosis value for aSAH. Bioinformatics approaches, including DEG analysis, pathway enrichment, immune infiltration, and GSEA, explored potential mechanisms. Molecular docking assessed interactions between dexmedetomidine and identified hub genes.ResultsA total of 505 individuals with aSAH were included in this study, with 114 dying in-hospital. Patients in the in-hospital mortality group exhibited older age, higher SAPS II scores, and altered physiological parameters. Dexmedetomidine was the most influential treatment variable, significantly associated with reduced in-hospital mortality. Bioinformatics identified three hub genes (MyD88, AR, AREG) related to aSAH and dexmedetomidine. These hub genes showed promising diagnostic accuracy in aSAH, with all AUC values over 0.67. Immune infiltration and GSEA highlighted the involvement of hub genes in inflammation and immune regulation. Molecular docking revealed AR as a direct target of dexmedetomidine (binding energy = −5.68 kcal/mol).ConclusionDexmedetomidine is correlated with reduced in-hospital mortality in aSAH, potentially by regulating AR and immune pathways. These findings highlight AR as a promising therapeutic target of dexmedetomidine for aSAH management. |
| format | Article |
| id | doaj-art-7bf0fe1263f9419ea18c33f46eb0e9fb |
| institution | Kabale University |
| issn | 1664-2295 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj-art-7bf0fe1263f9419ea18c33f46eb0e9fb2025-08-20T03:51:43ZengFrontiers Media S.A.Frontiers in Neurology1664-22952025-07-011610.3389/fneur.2025.15548091554809Dexmedetomidine reduces in-hospital mortality in aneurysmal subarachnoid hemorrhage patients by modulating three key genes and inflammatory pathways: insights from clinical and bioinformatics analysesZhi-ang Li0Hong-cai Wang1Xue-wei Zhang2Li-hong Hu3Department of Anesthesiology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, ChinaDepartment of Neurosurgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, ChinaDepartment of Anesthesiology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, ChinaDepartment of Anesthesiology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, ChinaBackgroundAneurysmal subarachnoid hemorrhage (aSAH) is a cerebrovascular disease with high mortality. Dexmedetomidine has a neuroprotective effect. This study aimed to explore the clinical and molecular association between dexmedetomidine and in-hospital mortality of aSAH.MethodsPatients with aSAH in the MIMIC-IV database were included and divided into non-in-hospital mortality and in-hospital mortality groups. Two machine learning algorithms random forest (RF) and XGBoost ranked treatment variables, and overlapping variables between these two algorithms were selected to evaluate their prognosis value for aSAH. Bioinformatics approaches, including DEG analysis, pathway enrichment, immune infiltration, and GSEA, explored potential mechanisms. Molecular docking assessed interactions between dexmedetomidine and identified hub genes.ResultsA total of 505 individuals with aSAH were included in this study, with 114 dying in-hospital. Patients in the in-hospital mortality group exhibited older age, higher SAPS II scores, and altered physiological parameters. Dexmedetomidine was the most influential treatment variable, significantly associated with reduced in-hospital mortality. Bioinformatics identified three hub genes (MyD88, AR, AREG) related to aSAH and dexmedetomidine. These hub genes showed promising diagnostic accuracy in aSAH, with all AUC values over 0.67. Immune infiltration and GSEA highlighted the involvement of hub genes in inflammation and immune regulation. Molecular docking revealed AR as a direct target of dexmedetomidine (binding energy = −5.68 kcal/mol).ConclusionDexmedetomidine is correlated with reduced in-hospital mortality in aSAH, potentially by regulating AR and immune pathways. These findings highlight AR as a promising therapeutic target of dexmedetomidine for aSAH management.https://www.frontiersin.org/articles/10.3389/fneur.2025.1554809/fullaneurysmal subarachnoid hemorrhagedexmedetomidinein-hospital mortalityinflammationimmune |
| spellingShingle | Zhi-ang Li Hong-cai Wang Xue-wei Zhang Li-hong Hu Dexmedetomidine reduces in-hospital mortality in aneurysmal subarachnoid hemorrhage patients by modulating three key genes and inflammatory pathways: insights from clinical and bioinformatics analyses Frontiers in Neurology aneurysmal subarachnoid hemorrhage dexmedetomidine in-hospital mortality inflammation immune |
| title | Dexmedetomidine reduces in-hospital mortality in aneurysmal subarachnoid hemorrhage patients by modulating three key genes and inflammatory pathways: insights from clinical and bioinformatics analyses |
| title_full | Dexmedetomidine reduces in-hospital mortality in aneurysmal subarachnoid hemorrhage patients by modulating three key genes and inflammatory pathways: insights from clinical and bioinformatics analyses |
| title_fullStr | Dexmedetomidine reduces in-hospital mortality in aneurysmal subarachnoid hemorrhage patients by modulating three key genes and inflammatory pathways: insights from clinical and bioinformatics analyses |
| title_full_unstemmed | Dexmedetomidine reduces in-hospital mortality in aneurysmal subarachnoid hemorrhage patients by modulating three key genes and inflammatory pathways: insights from clinical and bioinformatics analyses |
| title_short | Dexmedetomidine reduces in-hospital mortality in aneurysmal subarachnoid hemorrhage patients by modulating three key genes and inflammatory pathways: insights from clinical and bioinformatics analyses |
| title_sort | dexmedetomidine reduces in hospital mortality in aneurysmal subarachnoid hemorrhage patients by modulating three key genes and inflammatory pathways insights from clinical and bioinformatics analyses |
| topic | aneurysmal subarachnoid hemorrhage dexmedetomidine in-hospital mortality inflammation immune |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2025.1554809/full |
| work_keys_str_mv | AT zhiangli dexmedetomidinereducesinhospitalmortalityinaneurysmalsubarachnoidhemorrhagepatientsbymodulatingthreekeygenesandinflammatorypathwaysinsightsfromclinicalandbioinformaticsanalyses AT hongcaiwang dexmedetomidinereducesinhospitalmortalityinaneurysmalsubarachnoidhemorrhagepatientsbymodulatingthreekeygenesandinflammatorypathwaysinsightsfromclinicalandbioinformaticsanalyses AT xueweizhang dexmedetomidinereducesinhospitalmortalityinaneurysmalsubarachnoidhemorrhagepatientsbymodulatingthreekeygenesandinflammatorypathwaysinsightsfromclinicalandbioinformaticsanalyses AT lihonghu dexmedetomidinereducesinhospitalmortalityinaneurysmalsubarachnoidhemorrhagepatientsbymodulatingthreekeygenesandinflammatorypathwaysinsightsfromclinicalandbioinformaticsanalyses |